galactose has been researched along with DDD MPGNII in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Fukao, Y; Kano, T; Kato, R; Lee, M; Makita, Y; Nakayama, M; Suzuki, H; Suzuki, Y | 1 |
Kopač, M; Meglič, A; Rus, RR | 1 |
2 other study(ies) available for galactose and DDD MPGNII
Article | Year |
---|---|
Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy.
Topics: Adult; Antibodies, Monoclonal; Antiviral Agents; Arthritis, Rheumatoid; Crohn Disease; Diagnosis, Differential; Female; Galactose; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Hydrocarbons, Fluorinated; Immunoglobulin A; Immunohistochemistry; Kidney; Lupus Erythematosus, Systemic; Male; Middle Aged; Pulse Therapy, Drug; Remission Induction; Steroids; Tonsillectomy; Urea | 2021 |
Partial remission of resistant nephrotic syndrome after oral galactose therapy.
Topics: Administration, Oral; Adolescent; Biopsy; Child, Preschool; Drug Resistance; Female; Galactose; Glomerulonephritis, Membranoproliferative; Glomerulosclerosis, Focal Segmental; Glucocorticoids; Humans; Male; Nephrotic Syndrome; Proteinuria; Remission Induction | 2011 |